Orphalan Partners with MAP International for Global Health
Orphalan SA, a dedicated pharmaceutical company focusing on rare diseases, is making headway in improving health outcomes for underserved communities. In a noteworthy collaboration, Orphalan has joined forces with MAP International and the Wilson Disease Association (WDA) to deliver Cuvrior® (trientine tetrahydrochloride) to patients afflicted with Wilson Disease in developing nations.
Understanding Wilson Disease and Treatment Options
Wilson Disease is a genetic disorder that causes the body to accumulate excessive copper, leading to severe liver damage and neurological issues if not effectively addressed. Recognizing the urgent need for accessible treatment, Orphalan is committed to making Cuvrior® available, particularly in regions where healthcare services and treatment options are scant.
Philanthropic Collaboration for a Cause
This collaboration symbolizes a critical advancement in the fight for equitable healthcare access. Cuvrior®, an FDA-approved oral copper chelator, is the first of its kind designed for maintenance therapy, allowing for improved patient compliance with a twice-daily dosing schedule. Additionally, the medicine's stability at room temperature makes it easier to distribute in locations where refrigeration is not feasible.
Expanding Reach to Underserved Regions
Dmitry Paramonov, U.S. President of Orphalan, expressed the company's unwavering mission: "Our goal is to ensure that no patient is overlooked due to their geographical location." The partnership with MAP International allows Orphalan to expand its outreach, providing a lifeline to individuals with Wilson Disease in remote locations where medical interventions are limited or non-existent.
MAP International's Role in Healthcare Delivery
As a renowned humanitarian organization with over 70 years of experience, MAP International will coordinate the donation of Cuvrior® to ensure swift and secure delivery to patients in need. Chris Palombo, President and CEO of MAP International, emphasized the significance of this partnership, stating, "Delivering Cuvrior® to patients in remote communities is a pivotal advancement in treating Wilson Disease where options are limited."
Support from the Wilson Disease Association
The Wilson Disease Association plays a crucial role in this initiative by managing requests from doctors and patients, verifying their eligibility for treatment. Rhonda Rowland, the Association's President, noted the long-standing collaboration with MAP International. This partnership has been vital in providing access to essential medicines, and the extension of this working relationship with Orphalan marks an exciting new chapter in improving patient care.
A Commitment to Global Health Equity
Orphalan's donation of Cuvrior® to MAP International heralds a commitment to addressing global health disparities and ensuring that life-changing treatments are not a privilege reserved for the wealthy or those in developed regions. The availability of Cuvrior® to patients previously lacking access signifies a hopeful shift towards greater health equity.
How to Get Involved or Seek Help
Patients and healthcare providers interested in this program can reach out to the Wilson Disease Association via email for more information regarding eligibility and assistance in accessing Cuvrior®. Orphalan's proactive measures are positioning the company as a leader in promoting health equity and access for rare disease communities worldwide.
Frequently Asked Questions
What is the focus of Orphalan SA?
Orphalan SA is dedicated to developing and delivering innovative therapies for individuals experiencing rare and debilitating diseases.
What is Wilson Disease?
Wilson Disease is a genetic disorder that causes excessive copper accumulation leading to serious health complications, such as liver and neurological damage.
How does Cuvrior® help patients?
Cuvrior® is an oral copper chelator approved for maintenance therapy in adults with Wilson Disease, helping to manage excess copper levels safely.
Who is MAP International?
MAP International is a non-profit humanitarian organization that provides essential medicines globally to improve healthcare access for underserved populations.
How can patients obtain Cuvrior®?
Patients interested in accessing Cuvrior® should contact the Wilson Disease Association to verify eligibility and initiate the process.
